These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 23905577)

  • 1. Combinational delivery of lipid-enveloped polymeric nanoparticles carrying different peptides for anti-tumor immunotherapy.
    Tan S; Sasada T; Bershteyn A; Yang K; Ioji T; Zhang Z
    Nanomedicine (Lond); 2014 Apr; 9(5):635-47. PubMed ID: 23905577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery.
    Zhang Z; Tongchusak S; Mizukami Y; Kang YJ; Ioji T; Touma M; Reinhold B; Keskin DB; Reinherz EL; Sasada T
    Biomaterials; 2011 May; 32(14):3666-78. PubMed ID: 21345488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythrocyte Membrane-Enveloped Polymeric Nanoparticles as Nanovaccine for Induction of Antitumor Immunity against Melanoma.
    Guo Y; Wang D; Song Q; Wu T; Zhuang X; Bao Y; Kong M; Qi Y; Tan S; Zhang Z
    ACS Nano; 2015 Jul; 9(7):6918-33. PubMed ID: 26153897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses.
    Ma W; Chen M; Kaushal S; McElroy M; Zhang Y; Ozkan C; Bouvet M; Kruse C; Grotjahn D; Ichim T; Minev B
    Int J Nanomedicine; 2012; 7():1475-87. PubMed ID: 22619507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2K(b) and H-2D(b)-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma.
    Zhuang X; Wu T; Zhao Y; Hu X; Bao Y; Guo Y; Song Q; Li G; Tan S; Zhang Z
    J Control Release; 2016 Apr; 228():26-37. PubMed ID: 26921522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo delivery of peptides and Toll-like receptor ligands by mannose-functionalized polymeric nanoparticles induces prophylactic and therapeutic anti-tumor immune responses in a melanoma model.
    Silva JM; Zupancic E; Vandermeulen G; Oliveira VG; Salgado A; Videira M; Gaspar M; Graca L; Préat V; Florindo HF
    J Control Release; 2015 Jan; 198():91-103. PubMed ID: 25483429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanotechnology-Based Cancer Vaccine.
    Alshamsan A
    Methods Mol Biol; 2017; 1530():257-270. PubMed ID: 28150207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced anti-tumor immune responses and delay of tumor development in human epidermal growth factor receptor 2 mice immunized with an immunostimulatory peptide in poly(D,L-lactic-co-glycolic) acid nanoparticles.
    Campbell DF; Saenz R; Bharati IS; Seible D; Zhang L; Esener S; Messmer B; Larsson M; Messmer D
    Breast Cancer Res; 2015 Mar; 17(1):48. PubMed ID: 25882711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic long peptide-based vaccine formulations for induction of cell mediated immunity: A comparative study of cationic liposomes and PLGA nanoparticles.
    Varypataki EM; Silva AL; Barnier-Quer C; Collin N; Ossendorp F; Jiskoot W
    J Control Release; 2016 Mar; 226():98-106. PubMed ID: 26876760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hybrid melittin cytolytic Peptide-driven ultrasmall lipid nanoparticles block melanoma growth in vivo.
    Huang C; Jin H; Qian Y; Qi S; Luo H; Luo Q; Zhang Z
    ACS Nano; 2013 Jul; 7(7):5791-800. PubMed ID: 23790040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanovaccine loaded with poly I:C and STAT3 siRNA robustly elicits anti-tumor immune responses through modulating tumor-associated dendritic cells in vivo.
    Luo Z; Wang C; Yi H; Li P; Pan H; Liu L; Cai L; Ma Y
    Biomaterials; 2015 Jan; 38():50-60. PubMed ID: 25457983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PLGA-nanoparticle mediated delivery of anti-OX40 monoclonal antibody enhances anti-tumor cytotoxic T cell responses.
    Chen M; Ouyang H; Zhou S; Li J; Ye Y
    Cell Immunol; 2014 Feb; 287(2):91-9. PubMed ID: 24487032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of anti-tumor effect of particulate vaccine delivery system by 'bacteriomimetic' CpG functionalization of poly-lactic-co-glycolic acid nanoparticles.
    Kokate RA; Thamake SI; Chaudhary P; Mott B; Raut S; Vishwanatha JK; Jones HP
    Nanomedicine (Lond); 2015; 10(6):915-29. PubMed ID: 25867857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poly(D,L-lactide-co-glycolide acid) nanoparticles for DNA delivery: waiving preparation complexity and increasing efficiency.
    Gvili K; Benny O; Danino D; Machluf M
    Biopolymers; 2007 Apr 5-15; 85(5-6):379-91. PubMed ID: 17266128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surface modification of poly(D,L-lactic-co-glycolic acid) nanoparticles with protamine enhanced cross-presentation of encapsulated ovalbumin by bone marrow-derived dendritic cells.
    Han R; Zhu J; Yang X; Xu H
    J Biomed Mater Res A; 2011 Jan; 96(1):142-9. PubMed ID: 21105162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal immunization with poly(γ-glutamic acid) nanoparticles entrapping antigenic proteins can induce potent tumor immunity.
    Matsuo K; Koizumi H; Akashi M; Nakagawa S; Fujita T; Yamamoto A; Okada N
    J Control Release; 2011 Jun; 152(2):310-6. PubMed ID: 21402114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationalizing the use of functionalized poly-lactic-co-glycolic acid nanoparticles for dendritic cell-based targeted anticancer therapy.
    Kokate RA; Chaudhary P; Sun X; Thamake SI; Maji S; Chib R; Vishwanatha JK; Jones HP
    Nanomedicine (Lond); 2016; 11(5):479-94. PubMed ID: 26892440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells.
    Elamanchili P; Lutsiak CM; Hamdy S; Diwan M; Samuel J
    J Immunother; 2007; 30(4):378-95. PubMed ID: 17457213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations.
    Hamdy S; Haddadi A; Hung RW; Lavasanifar A
    Adv Drug Deliv Rev; 2011 Sep; 63(10-11):943-55. PubMed ID: 21679733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells.
    Fujisawa Y; Nabekura T; Nakao T; Nakamura Y; Takahashi T; Kawachi Y; Otsuka F; Onodera M
    Exp Dermatol; 2009 Apr; 18(4):396-403. PubMed ID: 19054057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.